Technical Analysis for BLRX - BioLineRx Ltd.

Grade Last Price % Change Price Change
grade F 2.63 -1.50% -0.04
BLRX closed down 1.5 percent on Monday, November 18, 2019, on 1.36 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BLRX trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Spinning Top Other 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.50%
Crossed Above 20 DMA Bullish -1.50%
Outside Day Range Expansion -1.50%
Fell Below 20 DMA Bearish 1.81%
MACD Bullish Signal Line Cross Bullish 1.81%
Narrow Range Bar Range Contraction 1.81%

Older signals for BLRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Biotechnology Health Pain Infectious Diseases Autoimmune Diseases Drug Discovery Clinical Trial Pharmacology Acute Myeloid Leukemia Schizophrenia Inflammatory Bowel Disease Design Of Experiments Clinical Research Central Nervous System Diseases Hematological Cancers Treatment Of Acute Myeloid Leukemia Biotechnology Companies Compugen Treatment Of Inflammatory Bowel Disease
Is BLRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 13.05
52 Week Low 2.32
Average Volume 55,623
200-Day Moving Average 4.5456
50-Day Moving Average 2.7147
20-Day Moving Average 2.6287
10-Day Moving Average 2.5623
Average True Range 0.1813
ADX 13.47
+DI 20.5656
-DI 15.8932
Chandelier Exit (Long, 3 ATRs ) 2.4961
Chandelier Exit (Short, 3 ATRs ) 2.8739
Upper Bollinger Band 2.8519
Lower Bollinger Band 2.4055
Percent B (%b) 0.5
BandWidth 16.981778
MACD Line -0.0412
MACD Signal Line -0.0538
MACD Histogram 0.0125
Fundamentals Value
Market Cap 251.47 Million
Num Shares 95.6 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -9.39
Price-to-Sales 0.00
Price-to-Book 1.78
PEG Ratio 0.18
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.78
Resistance 3 (R3) 2.78 2.72 2.76
Resistance 2 (R2) 2.72 2.69 2.73 2.75
Resistance 1 (R1) 2.68 2.66 2.70 2.68 2.74
Pivot Point 2.62 2.62 2.64 2.63 2.62
Support 1 (S1) 2.58 2.59 2.60 2.58 2.52
Support 2 (S2) 2.52 2.56 2.53 2.51
Support 3 (S3) 2.48 2.52 2.51
Support 4 (S4) 2.48